Journal of Neuroimmune Pharmacology

, Volume 8, Issue 4, pp 900–920 | Cite as

Evidence for a Dysregulated Immune System in the Etiology of Psychiatric Disorders

INVITED REVIEW

Abstract

There is extensive bi-directional communication between the brain and the immune system in both health and disease. In recent years, the role of an altered immune system in the etiology of major psychiatric disorders has become more apparent. Studies have demonstrated that some patients with major psychiatric disorders exhibit characteristic signs of immune dysregulation and that this may be a common pathophysiological mechanism that underlies the development and progression of these disorders. Furthermore, many psychiatric disorders are also often accompanied by chronic medical conditions related to immune dysfunction such as autoimmune diseases, diabetes and atherosclerosis. One of the major psychiatric disorders that has been associated with an altered immune system is schizophrenia, with approximately one third of patients with this disorder showing immunological abnormalities such as an altered cytokine profile in serum and cerebrospinal fluid. An altered cytokine profile is also found in a proportion of patients with major depressive disorder and is thought to be potentially related to the pathophysiology of this disorder. Emerging evidence suggests that altered immune parameters may also be implicated in the neurobiological etiology of autism spectrum disorders. Further support for a role of immune dysregulation in the pathophysiology of these psychiatric disorders comes from studies showing the immunomodulating effects of antipsychotics and antidepressants, and the mood altering effects of anti-inflammatory therapies. This review will not attempt to discuss all of the psychiatric disorders that have been associated with an augmented immune system, but will instead focus on several key disorders where dysregulation of this system has been implicated in their pathophysiology including depression, schizophrenia and autism spectrum disorder.

Keywords

Immune system Cytokines Depression Schizophrenia Autism Maternal inflammation Animal models 

References

  1. Abazyan B, Nomura J, Kannan G, Ishizuka K, Tamashiro KL, Nucifora F, Pogorelov V, Ladenheim B, Yang C, Krasnova IN, Cadet JL, Pardo C, Mori S, Kamiya A, Vogel MW, Sawa A, Ross CA, Pletnikov MV (2010) Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol Psychiatry 68:1172–1181PubMedCrossRefGoogle Scholar
  2. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S (2012) Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 141:308–314PubMedCrossRefGoogle Scholar
  3. Abdallah MW, Larsen N, Grove J, Norgaard-Pedersen B, Thorsen P, Mortensen EL, Hougaard DM (2012) Amniotic fluid chemokines and autism spectrum disorders: an exploratory study utilizing a Danish Historic Birth Cohort. Brain Behav Immun 26:170–176PubMedCrossRefGoogle Scholar
  4. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A (2009) Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26:607–611PubMedCrossRefGoogle Scholar
  5. Alavi M, Grebely J, Matthews GV, Petoumenos K, Yeung B, Day C, Lloyd AR, Van Beek I, Kaldor JM, Hellard M, Dore GJ, Haber PS (2012) Effect of pegylated interferon-alpha-2a treatment on mental health during recent hepatitis C virus infection. J Gastroenterol Hepatol 27:957–965PubMedCrossRefGoogle Scholar
  6. Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell’osso B, Kanba S, Monji A, Fatemi SH, Buckley P, Debnath M, Das UN, Meyer U, Muller N, Kanchanatawan B, Maes M (2013) Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuro-psychopharmacol Biol Psychiatry 42:1–4Google Scholar
  7. Andre C, O’Connor JC, Kelley KW, Lestage J, Dantzer R, Castanon N (2008) Spatio-temporal differences in the profile of murine brain expression of proinflammatory cytokines and indoleamine 2,3-dioxygenase in response to peripheral lipopolysaccharide administration. J Neuroimmunol 200:90–99PubMedCrossRefGoogle Scholar
  8. Anisman H, Merali Z, Poulter MO, Hayley S (2005) Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 11:963–972PubMedCrossRefGoogle Scholar
  9. Anisman H, Gibb J, Hayley S (2008) Influence of continuous infusion of interleukin-1beta on depression-related processes in mice: corticosterone, circulating cytokines, brain monoamines, and cytokine mRNA expression. Psychopharmacology 199:231–244PubMedCrossRefGoogle Scholar
  10. Arakawa S, Shirayama Y, Fujita Y, Ishima T, Horio M, Muneoka K, Iyo M, Hashimoto K (2012) Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. Pharmacol Biochem Behav 100:601–606PubMedCrossRefGoogle Scholar
  11. Arrode-Bruses G, Bruses JL (2012) Maternal immune activation by poly(I:C) induces expression of cytokines IL-1beta and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain. J Neuroinflammation 9:83PubMedCrossRefGoogle Scholar
  12. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J (2011a) Altered T cell responses in children with autism. Brain Behav Immun 25:840–849PubMedCrossRefGoogle Scholar
  13. Ashwood P, Corbett BA, Kantor A, Schulman H, Van de Water J, Amaral DG (2011b) In search of cellular immunophenotypes in the blood of children with autism. PLoS One 6:e19299PubMedCrossRefGoogle Scholar
  14. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J (2011c) Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 25:40–45PubMedCrossRefGoogle Scholar
  15. Atladottir HO, Thorsen P, Ostergaard L, Schendel DE, Lemcke S, Abdallah M, Parner ET (2010) Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J Autism Dev Disord 40:1423–1430PubMedCrossRefGoogle Scholar
  16. Atzeni F et al (2012) Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and Infliximab in the GISEA registry. Autoimmun Rev 12:225–229PubMedCrossRefGoogle Scholar
  17. Bah TM, Benderdour M, Kaloustian S, Karam R, Rousseau G, Godbout R (2011) Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression. Behav Brain Res 225:243–251PubMedCrossRefGoogle Scholar
  18. Baker I, Masserano J, Wyatt RJ (1996) Serum cytokine concentrations in patients with schizophrenia. Schizophr Res 20:199–203PubMedCrossRefGoogle Scholar
  19. Bale JF Jr (2009) Fetal infections and brain development. Clin Perinatol 36:639–653PubMedCrossRefGoogle Scholar
  20. Barr CE, Mednick SA, Munk-Jorgensen P (1990) Exposure to influenza epidemics during gestation and adult schizophrenia. A 40-year study. Arch Gen Psychiatry 47:869–874PubMedCrossRefGoogle Scholar
  21. Barrientos RM, Frank MG, Hein AM, Higgins EA, Watkins LR, Rudy JW, Maier SF (2009) Time course of hippocampal IL-1 beta and memory consolidation impairments in aging rats following peripheral infection. Brain Behav Immun 23:46–54PubMedCrossRefGoogle Scholar
  22. Barrientos RM, Hein AM, Frank MG, Watkins LR, Maier SF (2012) Intracisternal interleukin-1 receptor antagonist prevents postoperative cognitive decline and neuroinflammatory response in aged rats. J Neurosci: Off J Soc Neurosci 32:14641–14648CrossRefGoogle Scholar
  23. Benavides J, Toulmond S (1993) Role of cytokines in the central nervous system. Therapie 48:575–584PubMedGoogle Scholar
  24. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D (2012a) Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 37(12):1901–1911Google Scholar
  25. Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, Steiner J, Connor TJ, Harkin A, Versnel MA, Drexhage HA (2012b) The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol 92:959–975PubMedCrossRefGoogle Scholar
  26. Birerdinc A, Afendy A, Stepanova M, Younossi I, Baranova A, Younossi ZM (2012) Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). Brain Behav 2:525–531PubMedCrossRefGoogle Scholar
  27. Bitanihirwe BK, Peleg-Raibstein D, Mouttet F, Feldon J, Meyer U (2010) Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol 35:2462–2478CrossRefGoogle Scholar
  28. Bluthe RM, Laye S, Michaud B, Combe C, Dantzer R, Parnet P (2000) Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur J Neurosci 12:4447–4456PubMedGoogle Scholar
  29. Boksa P (2008) Maternal infection during pregnancy and schizophrenia. J Psychiatry Neurosci: JPN 33:183–185PubMedGoogle Scholar
  30. Boksa P (2010) Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain Behav Immun 24:881–897PubMedCrossRefGoogle Scholar
  31. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA: J Am Med Assoc 295:2275–2285CrossRefGoogle Scholar
  32. Braunschweig D, Van de Water J (2012) Maternal autoantibodies in autism. Arch Neurol 69:693–699PubMedCrossRefGoogle Scholar
  33. Brown AS (2011) The environment and susceptibility to schizophrenia. Prog Neurobiol 93:23–58PubMedCrossRefGoogle Scholar
  34. Brown AS, Derkits EJ (2010) Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 167:261–280PubMedCrossRefGoogle Scholar
  35. Brown AS, Cohen P, Harkavy-Friedman J, Babulas V, Malaspina D, Gorman JM, Susser ES (2001) A.E. Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia. Biol Psychiatry 49:473–486PubMedCrossRefGoogle Scholar
  36. Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, Babulas VP, Susser ES (2004a) Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 61:774–780PubMedCrossRefGoogle Scholar
  37. Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, Perrin M, Gorman JM, Susser ES (2004b) Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 161:889–895PubMedCrossRefGoogle Scholar
  38. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Wagner RL, Yolken RH (2001) Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav Immun 15:411–420PubMedCrossRefGoogle Scholar
  39. Buka SL, Cannon TD, Torrey EF, Yolken RH (2008) Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol Psychiatry 63:809–815PubMedCrossRefGoogle Scholar
  40. Busse S, Busse M, Schiltz K, Bielau H, Gos T, Brisch R, Mawrin C, Schmitt A, Jordan W, Muller UJ, Bernstein HG, Bogerts B, Steiner J (2012) Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Brain Behav Immun 26:1273–1279PubMedCrossRefGoogle Scholar
  41. Capuron L, Ravaud A, Dantzer R (2000) Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol: Off J Am Soc Clin Oncol 18:2143–2151Google Scholar
  42. Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ (2001) Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26:797–808PubMedCrossRefGoogle Scholar
  43. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R (2002) Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 7:468–473PubMedCrossRefGoogle Scholar
  44. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, Miller AH (2003) Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 54:906–914PubMedCrossRefGoogle Scholar
  45. Capuron L, Ravaud A, Miller AH, Dantzer R (2004) Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 18:205–213PubMedCrossRefGoogle Scholar
  46. Carta MG, Loviselli A, Hardoy MC, Massa S, Cadeddu M, Sardu C, Carpiniello B, Dell’Osso L, Mariotti S (2004) The link between thyroid autoimmunity (antithyroid peroxidase autoantibodies) with anxiety and mood disorders in the community: a field of interest for public health in the future. BMC Psychiatry 4:25PubMedCrossRefGoogle Scholar
  47. Carta MG, Hardoy MC, Carpiniello B, Murru A, Marci AR, Carbone F, Deiana L, Cadeddu M, Mariotti S (2005) A case control study on psychiatric disorders in Hashimoto disease and Euthyroid Goitre: not only depressive but also anxiety disorders are associated with thyroid autoimmunity. Clin Pract Epidemiol Ment Health 1:23PubMedCrossRefGoogle Scholar
  48. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Adorni A, Pegoraro M, Bosis S, Colombo F, Trabattoni D, Zagliani A, Clerici M (2002) Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog Neuro-psychopharmacol Biol Psychiatry 26:33–39CrossRefGoogle Scholar
  49. Chaves C, Marque CR, Trzesniak C, Machado de Sousa JP, Zuardi AW, Crippa JA, Dursun SM, Hallak JE (2009) Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. Braz J Med Biol Res = Rev Bras Pesquisas Med Biols/Soc Bras Biofisica [et al] 42:1002–1014Google Scholar
  50. Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Tzeng NS, Lee IH, Chen PS, Yeh TL, Huang SY, Yang YK, Lu RB (2012) Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J Neuroimmune Pharmacol: Off J Soc NeuroImmune Pharmacol 7:656–664CrossRefGoogle Scholar
  51. Chez MG, Dowling T, Patel PB, Khanna P, Kominsky M (2007) Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 36:361–365PubMedCrossRefGoogle Scholar
  52. Chowdari KV, Xu K, Zhang F, Ma C, Li T, Xie BY, Wood J, Trucco M, Tsoi WF, Saha N, Rudert WA, Nimgaonkar VL (2001) Immune related genetic polymorphisms and schizophrenia among the Chinese. Hum Immunol 62:714–724PubMedCrossRefGoogle Scholar
  53. Christmas DM, Potokar J, Davies SJ (2011) A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. Neuropsychiatr Dis Treat 7:431–439PubMedGoogle Scholar
  54. Clancy B, Finlay BL, Darlington RB, Anand KJ (2007) Extrapolating brain development from experimental species to humans. Neurotoxicology 28:931–937PubMedCrossRefGoogle Scholar
  55. Connor TJ, Leonard BE (1998) Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 62:583–606PubMedCrossRefGoogle Scholar
  56. Corona AW, Norden DM, Skendelas JP, Huang Y, O’Connor JC, Lawson M, Dantzer R, Kelley KW, Godbout JP (2012) Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice. Brain Behav Immun. doi:10.1016/j.bbi.2012.08.008
  57. Covic T, Cumming SR, Pallant JF, Manolios N, Emery P, Conaghan PG, Tennant A (2012) Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the Depression, Anxiety and Stress Scale (DASS) and the hospital, Anxiety and Depression Scale (HADS). BMC Psychiatry 12:6PubMedCrossRefGoogle Scholar
  58. Craddock RM, Lockstone HE, Rider DA, Wayland MT, Harris LJ, McKenna PJ, Bahn S (2007) Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms. PLoS One 2:e692PubMedCrossRefGoogle Scholar
  59. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56PubMedCrossRefGoogle Scholar
  60. Dantzer R, O’Connor JC, Lawson MA, Kelley KW (2011) Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36:426–436PubMedCrossRefGoogle Scholar
  61. Debnath M, Cannon DM, Venkatasubramanian G (2013) Variation in the major histocompatibility complex [MHC] gene family in schizophrenia: associations and functional implications. Prog Neuro-psychopharmacol Biol Psychiatry 42:49–62Google Scholar
  62. Dempsey PW, Vaidya SA, Cheng G (2003) The art of war: Innate and adaptive immune responses. Cell Mol Life Sci: CMLS 60:2604–2621PubMedCrossRefGoogle Scholar
  63. Depino AM (2013) Peripheral and central inflammation in autism spectrum disorders. Mol Cell Neurosci 53:69–76Google Scholar
  64. Dickens C, McGowan L, Clark-Carter D, Creed F (2002) Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med 64:52–60PubMedGoogle Scholar
  65. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC (2009) Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med: Off Publ, Soc Nucl Med 50:1801–1807Google Scholar
  66. Douglas KM, Taylor AJ, O’Malley PG (2004) Relationship between depression and C-reactive protein in a screening population. Psychosom Med 66:679–683PubMedCrossRefGoogle Scholar
  67. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457PubMedCrossRefGoogle Scholar
  68. Drexhage RC, Padmos RC, de Wit H, Versnel MA, Hooijkaas H, van der Lely AJ, van Beveren N, deRijk RH, Cohen D (2008) Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients? Schizophr Res 102:352–355PubMedCrossRefGoogle Scholar
  69. Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC, van Beveren N, Cohen D, Versnel MA, Nolen WA, Drexhage HA (2010) Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol 13:1369–1381PubMedCrossRefGoogle Scholar
  70. Drexhage RC, Hoogenboezem TA, Cohen D, Versnel MA, Nolen WA, van Beveren NJ, Drexhage HA (2011) An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int J Neuropsychopharmacol 14:746–755PubMedCrossRefGoogle Scholar
  71. Duivis HE, de Jonge P, Penninx BW, Na BY, Cohen BE, Whooley MA (2011) Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am J Psychiatry 168:913–920PubMedCrossRefGoogle Scholar
  72. Duivis HE, Kupper N, Penninx BW, Na B, de Jonge P, Whooley MA (2012) Depressive symptoms and white blood cell count in coronary heart disease patients: prospective findings from the Heart and Soul Study. Psychoneuroendocrinology 35(4):479–487Google Scholar
  73. Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68–72PubMedCrossRefGoogle Scholar
  74. Dunn AJ, Swiergiel AH, de Beaurepaire R (2005) Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 29:891–909PubMedCrossRefGoogle Scholar
  75. Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, Mortensen PB (2006) Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 163:521–528PubMedCrossRefGoogle Scholar
  76. Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB (2010) Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord 12:638–646PubMedCrossRefGoogle Scholar
  77. Eller T, Vasar V, Shlik J, Maron E (2009) The role of IL-2 and soluble IL-2R in depression and antidepressant response. Curr Opin Investig Drugs 10:638–643PubMedGoogle Scholar
  78. Ellman LM, Deicken RF, Vinogradov S, Kremen WS, Poole JH, Kern DM, Tsai WY, Schaefer CA, Brown AS (2010) Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res 121:46–54PubMedCrossRefGoogle Scholar
  79. Enstrom AM, Onore CE, Van de Water JA, Ashwood P (2010) Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun 24:64–71PubMedCrossRefGoogle Scholar
  80. Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, Calguneri M, Kalyoncu U (2012) Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int 32:323–330PubMedCrossRefGoogle Scholar
  81. Evans DL, Ten Have TR, Douglas SD, Gettes DR, Morrison M, Chiappini MS, Brinker-Spence P, Job C, Mercer DE, Wang YL, Cruess D, Dube B, Dalen EA, Brown T, Bauer R, Petitto JM (2002) Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry 159:1752–1759PubMedCrossRefGoogle Scholar
  82. Eyles D, Feldon J, Meyer U (2012) Schizophrenia: do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed developmental rodent models. Transl Psychiatry 2:e81PubMedCrossRefGoogle Scholar
  83. Fatemi SH, Reutiman TJ, Folsom TD, Huang H, Oishi K, Mori S, Smee DF, Pearce DA, Winter C, Sohr R, Juckel G (2008) Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophr Res 99:56–70PubMedCrossRefGoogle Scholar
  84. Fatjo-Vilas M, Pomarol-Clotet E, Salvador R, Monte GC, Gomar JJ, Sarro S, Ortiz-Gil J, Aguirre C, Landin-Romero R, Guerrero-Pedraza A, Papiol S, Blanch J, McKenna PJ, Fananas L (2012) Effect of the interleukin-1beta gene on dorsolateral prefrontal cortex function in schizophrenia: a genetic neuroimaging study. Biol Psychiatry 72:758–765PubMedCrossRefGoogle Scholar
  85. Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A (2008) Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 159:704–710PubMedCrossRefGoogle Scholar
  86. Fields C, Drye L, Vaidya V, Lyketsos C (2012) Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr Psychiatr: Off J Am Assoc Geriatr Psychiatr 20:505–513CrossRefGoogle Scholar
  87. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, Cairns M, Weickert CS (2013) Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 18(2)206–214Google Scholar
  88. Fischler B, Bocken R, Schneider I, De Waele M, Thielemans K, Derde MP (1992) Immune changes induced by electroconvulsive therapy (ECT). Ann N Y Acad Sci 650:326–330PubMedCrossRefGoogle Scholar
  89. Fluitman SB, Heijnen CJ, Denys DA, Nolen WA, Balk FJ, Westenberg HG (2011) Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. J Affect Disord 131:388–392PubMedCrossRefGoogle Scholar
  90. Forrest CM, Khalil OS, Pisar M, Smith RA, Darlington LG, Stone TW (2012) Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-D-aspartate receptors and neurogenesis markers in offspring. Mol Brain 5:22PubMedCrossRefGoogle Scholar
  91. Freidin M, Bennett MV, Kessler JA (1992) Cultured sympathetic neurons synthesize and release the cytokine interleukin 1 beta. Proc Natl Acad Sci U S A 89:10440–10443PubMedCrossRefGoogle Scholar
  92. Frodl T, Carballedo A, Hughes MM, Saleh K, Fagan A, Skokauskas N, McLoughlin DM, Meaney J, O’Keane V, Connor TJ (2012) Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl Psychiatry 2:e88PubMedCrossRefGoogle Scholar
  93. Fu X, Zunich SM, O’Connor JC, Kavelaars A, Dantzer R, Kelley KW (2010) Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. J Neuroinflammation 7:43PubMedCrossRefGoogle Scholar
  94. Garden GA, Moller T (2006) Microglia biology in health and disease. J Neuroimmune Pharmacol: Off J Soc NeuroImmune Pharmacol 1:127–137CrossRefGoogle Scholar
  95. Gibney SM, McGuinness B, Prendergast C, Harkin A, Connor TJ (2013) Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behavior Immun 28:170–181Google Scholar
  96. Godha D, Shi L, Mavronicolas H (2010) Association between tendency towards depression and severity of rheumatoid arthritis from a national representative sample: the Medical Expenditure Panel Survey. Curr Med Res Opin 26:1685–1690PubMedCrossRefGoogle Scholar
  97. Golan HM, Lev V, Hallak M, Sorokin Y, Huleihel M (2005) Specific neurodevelopmental damage in mice offspring following maternal inflammation during pregnancy. Neuropharmacology 48:903–917PubMedCrossRefGoogle Scholar
  98. Graciarena M, Depino AM, Pitossi FJ (2010) Prenatal inflammation impairs adult neurogenesis and memory related behavior through persistent hippocampal TGFbeta1 downregulation. Brain Behav Immun 24:1301–1309PubMedCrossRefGoogle Scholar
  99. Grigoleit JS, Kullmann JS, Wolf OT, Hammes F, Wegner A, Jablonowski S, Engler H, Gizewski E, Oberbeck R, Schedlowski M (2011) Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PLoS One 6:e28330PubMedCrossRefGoogle Scholar
  100. Guo JY, Li CY, Ruan YP, Sun M, Qi XL, Zhao BS, Luo F (2009) Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 612:54–60PubMedCrossRefGoogle Scholar
  101. Hanisch UK (2002) Microglia as a source and target of cytokines. Glia 40:140–155PubMedCrossRefGoogle Scholar
  102. Hannestad J, DellaGioia N, Bloch M (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol 36:2452–2459CrossRefGoogle Scholar
  103. Hanninen K, Katila H, Saarela M, Rontu R, Mattila KM, Fan M, Hurme M, Lehtimaki T (2008) Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. Eur Arch Psychiatr Clin Neurosci 258:10–15Google Scholar
  104. Hao LY, Hao XQ, Li SH, Li XH (2010) Prenatal exposure to lipopolysaccharide results in cognitive deficits in age-increasing offspring rats. Neuroscience 166:763–770PubMedCrossRefGoogle Scholar
  105. Hayley S, Scharf J, Anisman H (2012) Central administration of murine interferon-alpha induces depressive-like behavioral, brain cytokine and neurochemical alterations in mice: a mini-review and original experiments. Brain Behav Immun. doi:10.1016/j.bbi.2012.07.023
  106. Herbert J, Goodyer IM, Grossman AB, Hastings MH, de Kloet ER, Lightman SL, Lupien SJ, Roozendaal B, Seckl JR (2006a) Do corticosteroids damage the brain? J Neuroendocrinol 18:393–411PubMedCrossRefGoogle Scholar
  107. Herbert MR, Russo JP, Yang S, Roohi J, Blaxill M, Kahler SG, Cremer L, Hatchwell E (2006b) Autism and environmental genomics. Neurotoxicology 27:671–684PubMedCrossRefGoogle Scholar
  108. Hestad KA, Tonseth S, Stoen CD, Ueland T, Aukrust P (2003) Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 19:183–188PubMedCrossRefGoogle Scholar
  109. Hillegers MH, Reichart CG, Wals M, Verhulst FC, Ormel J, Nolen WA, Drexhage HA (2007) Signs of a higher prevalence of autoimmune thyroiditis in female offspring of bipolar parents. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 17:394–399CrossRefGoogle Scholar
  110. Himmerich H, Milenovic S, Fulda S, Plumakers B, Sheldrick AJ, Michel TM, Kircher T, Rink L (2010) Regulatory T cells increased while IL-1beta decreased during antidepressant therapy. J Psychiatr Res 44:1052–1057PubMedCrossRefGoogle Scholar
  111. Hinwood M, Morandini J, Day TA, Walker FR (2012) Evidence that microglia mediate the neurobiological effects of chronic psychological stress on the medial prefrontal cortex. Cereb Cortex 22:1442–1454PubMedCrossRefGoogle Scholar
  112. Hopkins SJ, Rothwell NJ (1995) Cytokines and the nervous system. I: expression and recognition. Trends Neurosci 18:83–88PubMedCrossRefGoogle Scholar
  113. Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71:171–186PubMedCrossRefGoogle Scholar
  114. Hsiao EY, McBride SW, Chow J, Mazmanian SK, Patterson PH (2012) Modeling an autism risk factor in mice leads to permanent immune dysregulation. Proc Natl Acad Sci U S A 109:12776–12781PubMedCrossRefGoogle Scholar
  115. Hughes MM, Carballedo A, McLoughlin DM, Amico F, Harkin A, Frodl T, Connor TJ (2012) Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav Immun 26:979–987PubMedCrossRefGoogle Scholar
  116. Ibi D, Nagai T, Koike H, Kitahara Y, Mizoguchi H, Niwa M, Jaaro-Peled H, Nitta A, Yoneda Y, Nabeshima T, Sawa A, Yamada K (2010) Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood. Behav Brain Res 206:32–37PubMedCrossRefGoogle Scholar
  117. Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium (2012) Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. Biol Psychiatry 72:620–628CrossRefGoogle Scholar
  118. Jia P, Wang L, Fanous AH, Pato CN, Edwards TL, Zhao Z (2012a) Network-assisted investigation of combined causal signals from genome-wide association studies in schizophrenia. PLoS Comput Biol 8:e1002587PubMedCrossRefGoogle Scholar
  119. Jia P, Wang L, Fanous AH, Chen X, Kendler KS, Zhao Z (2012b) A bias-reducing pathway enrichment analysis of genome-wide association data confirmed association of the MHC region with schizophrenia. J Med Genet 49:96–103PubMedCrossRefGoogle Scholar
  120. Johansson D, Falk A, Marcus MM, Svensson TH (2012) Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat. Prog Neuro-psychopharmacol Biol Psychiatr 39:143–148CrossRefGoogle Scholar
  121. Jyonouchi H, Geng L, Streck DL, Toruner GA (2012) Immunological characterization and transcription profiling of peripheral blood (PB) monocytes in children with autism spectrum disorders (ASD) and specific polysaccharide antibody deficiency (SPAD): case study. J Neuroinflammation 9:4PubMedCrossRefGoogle Scholar
  122. Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL (2012) Depressive-like behavior induced by tumor necrosis factor-alpha in mice. Neuropharmacology 62:419–426PubMedCrossRefGoogle Scholar
  123. Katila H, Hurme M, Wahlbeck K, Appelberg B, Rimon R (1994) Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients. Neuropsychobiology 30:20–23PubMedCrossRefGoogle Scholar
  124. Katz PP, Yelin EH (2001) Activity loss and the onset of depressive symptoms: do some activities matter more than others? Arthritis Rheum 44:1194–1202PubMedCrossRefGoogle Scholar
  125. Kelly DL, Vyas G, Richardson CM, Koola M, McMahon RP, Buchanan RW, Wehring HJ (2011) Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res 133:257–258PubMedCrossRefGoogle Scholar
  126. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of microglia. Physiol Rev 91:461–553PubMedCrossRefGoogle Scholar
  127. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM (2011) Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer’s disease model. J Immunol 187:6539–6549PubMedCrossRefGoogle Scholar
  128. Kolvin I (1971) Studies in the childhood psychoses. I. Diagnostic criteria and classification. Br J Psychiatry: J Mental Sci 118:381–384CrossRefGoogle Scholar
  129. Kraus MR, Schafer A, Schottker K, Keicher C, Weissbrich B, Hofbauer I, Scheurlen M (2008) Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 57:531–536PubMedCrossRefGoogle Scholar
  130. Krishnadas R, Cavanagh J (2012) Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry 83:495–502PubMedCrossRefGoogle Scholar
  131. Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M, Chiou CF, Patel V, Jahreis A (2007) Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 157:1275–1277PubMedCrossRefGoogle Scholar
  132. Kronfol Z, Remick DG (2000) Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157:683–694PubMedCrossRefGoogle Scholar
  133. Kronfol Z, Nair MP, Weinberg V, Young EA, Aziz M (2002) Acute effects of electroconvulsive therapy on lymphocyte natural killer cell activity in patients with major depression. J Affect Disord 71:211–215PubMedCrossRefGoogle Scholar
  134. Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M (2011) In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuro-psychopharmacol Biol Psychiatr 35:744–759CrossRefGoogle Scholar
  135. Kupka RW, Nolen WA, Post RM, McElroy SL, Altshuler LL, Denicoff KD, Frye MA, Keck PE Jr, Leverich GS, Rush AJ, Suppes T, Pollio C, Drexhage HA (2002) High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 51:305–311PubMedCrossRefGoogle Scholar
  136. Kupper N, Widdershoven JW, Pedersen SS (2012) Cognitive/affective and somatic/affective symptom dimensions of depression are associated with current and future inflammation in heart failure patients. J Affect Disord 136:567–576PubMedCrossRefGoogle Scholar
  137. Laurent C, Thibaut F, Ravassard P, Campion D, Samolyk D, Lafargue C, Petit M, Martinez M, Mallet J (1997) Detection of two new polymorphic sites in the human interleukin-1 beta gene: lack of association with schizophrenia in a French population. Psychiatr Genet 7:103–105PubMedCrossRefGoogle Scholar
  138. Lehman CL, Cheung RC (2002) Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol 97:2640–2646PubMedCrossRefGoogle Scholar
  139. Lehtimaki K, Keranen T, Huuhka M, Palmio J, Hurme M, Leinonen E, Peltola J (2008) Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. J ECT 24:88–91PubMedCrossRefGoogle Scholar
  140. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 71:138–149PubMedCrossRefGoogle Scholar
  141. Levy BH, Tasker JG (2012) Synaptic regulation of the hypothalamic-pituitary-adrenal axis and its modulation by glucocorticoids and stress. Front Cell Neurosci 6:24PubMedCrossRefGoogle Scholar
  142. Li Q, Cheung C, Wei R, Hui ES, Feldon J, Meyer U, Chung S, Chua SE, Sham PC, Wu EX, McAlonan GM (2009a) Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant to schizophrenia: evidence from MRI in a mouse model. PLoS One 4:e6354PubMedCrossRefGoogle Scholar
  143. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, Ji L, Brown T, Malik M (2009b) Elevated immune response in the brain of autistic patients. J Neuroimmunol 207:111–116PubMedCrossRefGoogle Scholar
  144. Li Q, Cheung C, Wei R, Cheung V, Hui ES, You Y, Wong P, Chua SE, McAlonan GM, Wu EX (2010) Voxel-based analysis of postnatal white matter microstructure in mice exposed to immune challenge in early or late pregnancy. NeuroImage 52:1–8PubMedCrossRefGoogle Scholar
  145. Liu L, Jia F, Yuan G, Chen Z, Yao J, Li H, Fang C (2010) Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis. Psychiatry Res 176:1–7PubMedCrossRefGoogle Scholar
  146. Loftis JM, Huckans M, Ruimy S, Hinrichs DJ, Hauser P (2008) Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci Lett 430:264–268PubMedCrossRefGoogle Scholar
  147. Lu LX, Guo SQ, Chen W, Li Q, Cheng J, Guo JH (2004) [Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia]. Di 1 jun yi da xue xue bao = Acad J First Med Coll PLA 24:1251–1254Google Scholar
  148. Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, Meltzer HY, De Ley M, Berghmans R, Stans G, Desnyder R (1996) Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 21:39–50PubMedCrossRefGoogle Scholar
  149. Maes M, Bosmans E, Kenis G, De Jong R, Smith RS, Meltzer HY (1997) In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26:221–225PubMedCrossRefGoogle Scholar
  150. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R (2011) The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuro-psychopharmacol Biol Psychiatry 35:702–721CrossRefGoogle Scholar
  151. Malkova NV, Yu CZ, Hsiao EY, Moore MJ, Patterson PH (2012) Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav Immun 26:607–616PubMedCrossRefGoogle Scholar
  152. Manev R, Manev H (2009) Minocycline, schizophrenia and GluR1 glutamate receptors. Progr Neuro-psychopharmacol Biol Psychiatry 33:166, author reply 167CrossRefGoogle Scholar
  153. Margaretten M, Julian L, Katz P, Yelin E (2011) Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumatol 6:617–623CrossRefGoogle Scholar
  154. Matsumoto Y, Yamaguchi T, Watanabe S, Yamamoto T (2004) Involvement of arachidonic acid cascade in working memory impairment induced by interleukin-1 beta. Neuropharmacology 46:1195–1200PubMedCrossRefGoogle Scholar
  155. Mednick SA, Machon RA, Huttunen MO, Bonett D (1988) Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 45:189–192PubMedCrossRefGoogle Scholar
  156. Meijer A, Conradi HJ, Bos EH, Thombs BD, van Melle JP, de Jonge P (2011) Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. Gen Hosp Psychiatry 33:203–216PubMedCrossRefGoogle Scholar
  157. Meyer U, Feldon J (2009) Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology 206:587–602PubMedCrossRefGoogle Scholar
  158. Meyer U, Feldon J (2012) To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology 62:1308–1321PubMedCrossRefGoogle Scholar
  159. Meyer U, Nyffeler M, Engler A, Urwyler A, Schedlowski M, Knuesel I, Yee BK, Feldon J (2006) The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosc: Offi J Soc Neurosci 26:4752–4762CrossRefGoogle Scholar
  160. Meyer U, Feldon J, Yee BK (2009) A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull 35:959–972PubMedCrossRefGoogle Scholar
  161. Meyer U, Spoerri E, Yee BK, Schwarz MJ, Feldon J (2010) Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr Bull 36:607–623PubMedCrossRefGoogle Scholar
  162. Meyer U, Feldon J, Dammann O (2011) Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res 69:26R–33RPubMedCrossRefGoogle Scholar
  163. Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732–741PubMedCrossRefGoogle Scholar
  164. Miller AH, Haroon E, Raison CL, Felger JC (2013) Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depression Anxiety 30(4):297–306Google Scholar
  165. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J (2008) Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 31:287–292PubMedCrossRefGoogle Scholar
  166. Molloy CA, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K, Manning-Courtney P, Altaye M, Wills-Karp M (2006) Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol 172:198–205PubMedCrossRefGoogle Scholar
  167. Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, Courchesne E, Everall IP (2010) Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry 68:368–376PubMedCrossRefGoogle Scholar
  168. Morgan JT, Chana G, Abramson I, Semendeferi K, Courchesne E, Everall IP (2012) Abnormal microglial-neuronal spatial organization in the dorsolateral prefrontal cortex in autism. Brain Res 1456:72–81PubMedCrossRefGoogle Scholar
  169. Mortensen PB, Pedersen CB, Hougaard DM, Norgaard-Petersen B, Mors O, Borglum AD, Yolken RH (2010) A Danish National Birth Cohort study of maternal HSV-2 antibodies as a risk factor for schizophrenia in their offspring. Schizophr Res 122:257–263PubMedCrossRefGoogle Scholar
  170. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B (2007) Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370:851–858PubMedCrossRefGoogle Scholar
  171. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Moller HJ, Schwarz MJ (2002) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159:1029–1034PubMedCrossRefGoogle Scholar
  172. Muller N, Riedel M, Schwarz MJ, Engel RR (2005) Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatr Clin Neurosci 255:149–151CrossRefGoogle Scholar
  173. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Moller HJ, Arolt V, Riedel M (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11:680–684PubMedCrossRefGoogle Scholar
  174. Muller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Moller HJ, Klauss V, Schwarz MJ, Riedel M (2010) Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 121:118–124PubMedCrossRefGoogle Scholar
  175. Muller N, Wagner JK, Krause D, Weidinger E, Wildenauer A, Obermeier M, Dehning S, Gruber R, Schwarz MJ (2012) Impaired monocyte activation in schizophrenia. Psychiatry Res 198:341–346PubMedCrossRefGoogle Scholar
  176. Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, Arolt V, Muller N (2011) Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression–no influence of celecoxib treatment. J Affect Disord 134:217–225PubMedCrossRefGoogle Scholar
  177. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344:961–966PubMedCrossRefGoogle Scholar
  178. Myint AM, Steinbusch HW, Goeghegan L, Luchtman D, Kim YK, Leonard BE (2007a) Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 14:65–71PubMedCrossRefGoogle Scholar
  179. Myint AM, O’Mahony S, Kubera M, Kim YK, Kenny C, Kaim-Basta A, Steinbusch HW, Leonard BE (2007b) Role of paroxetine in interferon-alpha-induced immune and behavioural changes in male Wistar rats. J Psychopharmacol 21:843–850PubMedCrossRefGoogle Scholar
  180. Nagai T, Kitahara Y, Ibi D, Nabeshima T, Sawa A, Yamada K (2011) Effects of antipsychotics on the behavioral deficits in human dominant-negative DISC1 transgenic mice with neonatal polyI:C treatment. Behav Brain Res 225:305–310PubMedCrossRefGoogle Scholar
  181. Nawa H, Takei N (2006) Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 56:2–13PubMedCrossRefGoogle Scholar
  182. O’Callaghan E, Gibson T, Colohan HA, Walshe D, Buckley P, Larkin C, Waddington JL (1991) Season of birth in schizophrenia. Evidence for confinement of an excess of winter births to patients without a family history of mental disorder. Br J Psychiatr: J Mental Sci 158:764–769CrossRefGoogle Scholar
  183. O’Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N, Kelley KW, Dantzer R (2009a) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14:511–522PubMedCrossRefGoogle Scholar
  184. O’Connor JC, Andre C, Wang Y, Lawson MA, Szegedi SS, Lestage J, Castanon N, Kelley KW, Dantzer R (2009b) Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci: Off J Soc Neurosci 29:4200–4209CrossRefGoogle Scholar
  185. O’Connor JC, Lawson MA, Andre C, Briley EM, Szegedi SS, Lestage J, Castanon N, Herkenham M, Dantzer R, Kelley KW (2009c) Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 182:3202–3212PubMedCrossRefGoogle Scholar
  186. Oliver PL, Davies KE (2009) Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk. Hum Mol Genet 18:4576–4589PubMedCrossRefGoogle Scholar
  187. Olson JK, Miller SD (2004) Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 173:3916–3924PubMedGoogle Scholar
  188. Owen BM, Eccleston D, Ferrier IN, Young AH (2001) Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr Scand 103:226–228PubMedCrossRefGoogle Scholar
  189. Padmos RC, Bekris L, Knijff EM, Tiemeier H, Kupka RW, Cohen D, Nolen WA, Lernmark A, Drexhage HA (2004) A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biol Psychiatry 56:476–482PubMedCrossRefGoogle Scholar
  190. Pan A, Ye X, Franco OH, Li H, Yu Z, Wang J, Qi Q, Gu W, Pang X, Liu H, Lin X (2008) The association of depressive symptoms with inflammatory factors and adipokines in middle-aged and older Chinese. PLoS One 3:e1392PubMedCrossRefGoogle Scholar
  191. Paolicelli RC, Gross CT (2011) Microglia in development: linking brain wiring to brain environment. Neuron Glia Biol 7:77–83PubMedCrossRefGoogle Scholar
  192. Papiol S, Rosa A, Gutierrez B, Martin B, Salgado P, Catalan R, Arias B, Fananas L (2004) Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. J Med Genet 41:219–223PubMedCrossRefGoogle Scholar
  193. Papiol S, Molina V, Desco M, Rosa A, Reig S, Gispert JD, Sanz J, Palomo T, Fananas L (2005) Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene. NeuroImage 27:1002–1006PubMedCrossRefGoogle Scholar
  194. Patterson PH (2009) Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 204:313–321PubMedCrossRefGoogle Scholar
  195. Patterson PH (2012) Maternal infection and autism. Brain Behav Immun 26:393PubMedCrossRefGoogle Scholar
  196. Persoons P, Vermeire S, Demyttenaere K, Fischler B, Vandenberghe J, Van Oudenhove L, Pierik M, Hlavaty T, Van Assche G, Noman M, Rutgeerts P (2005) The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Aliment Pharmacol Ther 22:101–110PubMedCrossRefGoogle Scholar
  197. Ping F, Shang J, Zhou J, Zhang H, Zhang L (2012) 5-HT(1A) receptor and apoptosis contribute to interferon-alpha-induced “depressive-like” behavior in mice. Neurosci Lett 514:173–178PubMedCrossRefGoogle Scholar
  198. Piontkewitz Y, Arad M, Weiner I (2011) Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull 37:1257–1269PubMedCrossRefGoogle Scholar
  199. Piontkewitz Y, Bernstein HG, Dobrowolny H, Bogerts B, Weiner I, Keilhoff G (2012) Effects of risperidone treatment in adolescence on hippocampal neurogenesis, parvalbumin expression, and vascularization following prenatal immune activation in rats. Brain Behav Immun 26:353–363PubMedCrossRefGoogle Scholar
  200. Pletnikov MV, Ayhan Y, Nikolskaia O, Xu Y, Ovanesov MV, Huang H, Mori S, Moran TH, Ross CA (2008) Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry 13:173–186, 115PubMedCrossRefGoogle Scholar
  201. Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, Sklar P (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748–752PubMedGoogle Scholar
  202. Quan N, Banks WA (2007) Brain-immune communication pathways. Brain Behav Immun 21:727–735PubMedCrossRefGoogle Scholar
  203. Radewicz K, Garey LJ, Gentleman SM, Reynolds R (2000) Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 59:137–150PubMedGoogle Scholar
  204. Raison CL, Miller AH (2011) Is depression an inflammatory disorder? Curr Psychiatry Rep 13:467–475PubMedCrossRefGoogle Scholar
  205. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH (2005) Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 19:23–27PubMedCrossRefGoogle Scholar
  206. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31–41PubMedGoogle Scholar
  207. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM (1997) CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 25:123–129PubMedCrossRefGoogle Scholar
  208. Rapin I, Tuchman RF (2008) Autism: definition, neurobiology, screening, diagnosis. Pediatr Clin N Am 55:1129–1146, viiiCrossRefGoogle Scholar
  209. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T (2001) Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58:445–452PubMedCrossRefGoogle Scholar
  210. Reiner SL (2007) Development in motion: helper T cells at work. Cell 129:33–36PubMedCrossRefGoogle Scholar
  211. Richtand NM, Ahlbrand R, Horn P, Stanford K, Bronson SL, McNamara RK (2011) Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation. J Psychiatr Res 45:1194–1201PubMedCrossRefGoogle Scholar
  212. Richtand NM, Ahlbrand R, Horn P, Tambyraja R, Grainger M, Bronson SL, McNamara RK (2012) Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response. Physiol Behav 106:171–177PubMedCrossRefGoogle Scholar
  213. Riley JK, Nelson DM (2010) Toll-like receptors in pregnancy disorders and placental dysfunction. Clin Rev Allergy Immunol 39:185–193PubMedCrossRefGoogle Scholar
  214. Roberts RC (2007) Schizophrenia in translation: disrupted in schizophrenia (DISC1): integrating clinical and basic findings. Schizophr Bull 33:11–15PubMedCrossRefGoogle Scholar
  215. Roenker NL, Gudelsky G, Ahlbrand R, Bronson SL, Kern JR, Waterman H, Richtand NM (2011) Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801. Neurosci Lett 500:167–171PubMedCrossRefGoogle Scholar
  216. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H (1998) Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology 37:186–193PubMedCrossRefGoogle Scholar
  217. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E (2007) Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7:46PubMedCrossRefGoogle Scholar
  218. Saiz PA, Garcia-Portilla MP, Arango C, Morales B, Martinez-Barrondo S, Alvarez V, Coto E, Fernandez J, Bousono M, Bobes J (2006) Interleukin-1 gene complex in schizophrenia: an association study. Am J Medic Genet Part B, Neuropsychiatr Genet: Off Publ Int Soc Psychiatr Genet 141B:678–680CrossRefGoogle Scholar
  219. Salazar A, Gonzalez-Rivera BL, Redus L, Parrott JM, O’Connor JC (2012) Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm Behav 62:202–209PubMedCrossRefGoogle Scholar
  220. Sanacora G, Treccani G, Popoli M (2012) Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62:63–77PubMedCrossRefGoogle Scholar
  221. Sasayama D, Hori H, Teraishi T, Hattori K, Ota M, Iijima Y, Tatsumi M, Higuchi T, Amano N, Kunugi H (2011) Possible association between interleukin-1beta gene and schizophrenia in a Japanese population. Behavioral Brain Funct: BBF 7:35CrossRefGoogle Scholar
  222. Sawada M, Itoh Y, Suzumura A, Marunouchi T (1993) Expression of cytokine receptors in cultured neuronal and glial cells. Neurosci Lett 160:131–134PubMedCrossRefGoogle Scholar
  223. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, Heinz A, van Boemmel F, Berg T (2005) Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 42:793–798PubMedCrossRefGoogle Scholar
  224. Selten JP, Frissen A, Lensvelt-Mulders G, Morgan VA (2010) Schizophrenia and 1957 pandemic of influenza: meta-analysis. Schizophr Bull 36:219–228PubMedCrossRefGoogle Scholar
  225. Shatz CJ (2009) MHC class I: an unexpected role in neuronal plasticity. Neuron 64:40–45PubMedCrossRefGoogle Scholar
  226. Shi J et al (2009a) Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460:753–757PubMedGoogle Scholar
  227. Shi L, Smith SE, Malkova N, Tse D, Su Y, Patterson PH (2009b) Activation of the maternal immune system alters cerebellar development in the offspring. Brain Behav Immun 23:116–123PubMedCrossRefGoogle Scholar
  228. Silverman MN, Sternberg EM (2012) Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci 1261:55–63PubMedCrossRefGoogle Scholar
  229. Smith RS (1991) The macrophage theory of depression. Med Hypotheses 35:298–306PubMedCrossRefGoogle Scholar
  230. Smith RS, Maes M (1995) The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 45:135–141PubMedCrossRefGoogle Scholar
  231. Sommer IE, de Witte L, Begemann M, Kahn RS (2012) Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 73:414–419PubMedCrossRefGoogle Scholar
  232. Song C, Wang H (2011) Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuro-psychopharmacol & Biol Psychiatr 35:760–768CrossRefGoogle Scholar
  233. Stefansson H et al (2009) Common variants conferring risk of schizophrenia. Nature 460:744–747PubMedGoogle Scholar
  234. Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein HG, Bogerts B (2006) Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 112:305–316PubMedCrossRefGoogle Scholar
  235. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein HG, Bogerts B (2008) Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 42:151–157PubMedCrossRefGoogle Scholar
  236. Steptoe A, Kunz-Ebrecht SR, Owen N (2003) Lack of association between depressive symptoms and markers of immune and vascular inflammation in middle-aged men and women. Psychol Med 33:667–674PubMedCrossRefGoogle Scholar
  237. Steptoe A, Wikman A, Molloy GJ, Messerli-Burgy N, Kaski JC (2012) Inflammation and symptoms of depression and anxiety in patients with acute coronary heart disease. Brain Behav Immun. doi:10.1016/j.bbi.2012.09.002
  238. Stewart B, Mikocka-Walus A, Morgan J, Colman A, Phelps M, Harley H, Andrews J (2012) Anxiety and depression in Australian chronic hepatitis C outpatients: prevalence and predictors. Australasian Psychiatry: Bull R Aust N Z Coll Psychiatrists 20(6)496–500Google Scholar
  239. Stolp HB (2013) Neuropoietic cytokines in normal brain development and neurodevelopmental disorders. Mol Cell Neurosci 53:63–68Google Scholar
  240. Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1:609–620PubMedCrossRefGoogle Scholar
  241. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, Sanisoglu SY, Yesilova Z, Ozmenler N, Ozsahin A, Sengul A (2007) Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007:76396PubMedCrossRefGoogle Scholar
  242. Suvisaari J, Haukka J, Tanskanen A, Hovi T, Lonnqvist J (1999) Association between prenatal exposure to poliovirus infection and adult schizophrenia. Am J Psychiatry 156:1100–1102PubMedGoogle Scholar
  243. Sweeten TL, Posey DJ, McDougle CJ (2003) High blood monocyte counts and neopterin levels in children with autistic disorder. Am J Psychiatry 160:1691–1693PubMedCrossRefGoogle Scholar
  244. Takei N, Mortensen PB, Klaening U, Murray RM, Sham PC, O’Callaghan E, Munk-Jorgensen P (1996) Relationship between in utero exposure to influenza epidemics and risk of schizophrenia in Denmark. Biol Psychiatry 40:817–824PubMedCrossRefGoogle Scholar
  245. Tatsumi M, Sasaki T, Sakai T, Kamijima K, Fukuda R, Kunugi H, Hattori M, Nanko S (1997) Genes for interleukin-2 receptor beta chain, interleukin-1 beta, and schizophrenia: no evidence for the association or linkage. Am J Med Genet 74:338–341PubMedCrossRefGoogle Scholar
  246. Tetreault NA, Hakeem AY, Jiang S, Williams BA, Allman E, Wold BJ, Allman JM (2012) Microglia in the cerebral cortex in autism. J Autism Dev Disord 42:2569–2584PubMedCrossRefGoogle Scholar
  247. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E (2003) Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 170:429–433PubMedCrossRefGoogle Scholar
  248. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367:29–35PubMedCrossRefGoogle Scholar
  249. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X, Langohr K, Sola R, Vieta E, Martin-Santos R (2012) Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 73:1128–1138PubMedCrossRefGoogle Scholar
  250. van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL (2012) Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Annals Rheum Dis. doi:10.1136/annrheumdis-2012-201338
  251. van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645PubMedCrossRefGoogle Scholar
  252. Van Winkel R, Esquivel G, Kenis G, Wichers M, Collip D, Peerbooms O, Rutten B, Myin-Germeys I, Van Os J (2010) REVIEW: Genome-wide findings in schizophrenia and the role of gene-environment interplay. CNS Neurosci Ther 16:e185–e192PubMedCrossRefGoogle Scholar
  253. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA (2005) Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 57:67–81PubMedCrossRefGoogle Scholar
  254. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8:523–532PubMedCrossRefGoogle Scholar
  255. Vignau J, Costisella O, Canva V, Imbenotte M, Duhamel A, Lhermitte M (2009) Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients. L’Encéphale 35:477–483PubMedCrossRefGoogle Scholar
  256. Vilar-Pereira G, Silva AA, Pereira IR, Silva RR, Moreira OC, de Almeida LR, de Souza AS, Rocha MS, Lannes-Vieira J (2012) Trypanosoma cruzi-induced depressive-like behavior is independent of meningoencephalitis but responsive to parasiticide and TNF-targeted therapeutic interventions. Brain Behav Immun 26:1136–1149PubMedCrossRefGoogle Scholar
  257. Vitkovic L, Bockaert J, Jacque C (2000) “Inflammatory” cytokines: neuromodulators in normal brain? J Neurochem 74:457–471PubMedCrossRefGoogle Scholar
  258. Vonk R, van der Schot AC, Kahn RS, Nolen WA, Drexhage HA (2007) Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol Psychiatry 62:135–140PubMedCrossRefGoogle Scholar
  259. Vorhees CV, Graham DL, Braun AA, Schaefer TL, Skelton MR, Richtand NM, Williams MT (2012) Prenatal immune challenge in rats: altered responses to dopaminergic and glutamatergic agents, prepulse inhibition of acoustic startle, and reduced route-based learning as a function of maternal body weight gain after prenatal exposure to poly IC. Synapse 66:725–737PubMedCrossRefGoogle Scholar
  260. Vuillermot S, Feldon J, Meyer U (2011) Nurr1 is not essential for the development of prepulse inhibition deficits induced by prenatal immune activation. Brain Behav Immun 25:1316–1321PubMedCrossRefGoogle Scholar
  261. Wake H, Moorhouse AJ, Nabekura J (2011) Functions of microglia in the central nervous system–beyond the immune response. Neuron Glia Biol 7:47–53PubMedCrossRefGoogle Scholar
  262. Walker FR (2013) A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression? Neuropharmacology 67:304–317PubMedCrossRefGoogle Scholar
  263. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P (2011) Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 108:9262–9267PubMedCrossRefGoogle Scholar
  264. Weigelt K, Carvalho LA, Drexhage RC, Wijkhuijs A, de Wit H, van Beveren NJ, Birkenhager TK, Bergink V, Drexhage HA (2011) TREM-1 and DAP12 expression in monocytes of patients with severe psychiatric disorders. EGR3, ATF3 and PU.1 as important transcription factors. Brain Behav Immun 25:1162–1169PubMedCrossRefGoogle Scholar
  265. Wilson CJ, Finch CE, Cohen HJ (2002) Cytokines and cognition–the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 50:2041–2056PubMedCrossRefGoogle Scholar
  266. Winter C, Reutiman TJ, Folsom TD, Sohr R, Wolf RJ, Juckel G, Fatemi SH (2008) Dopamine and serotonin levels following prenatal viral infection in mouse–implications for psychiatric disorders such as schizophrenia and autism. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 18:712–716CrossRefGoogle Scholar
  267. Wolff AR, Cheyne KR, Bilkey DK (2011) Behavioural deficits associated with maternal immune activation in the rat model of schizophrenia. Behav Brain Re 225:382–387CrossRefGoogle Scholar
  268. Yang J, Si T, Ling Y, Ruan Y, Han Y, Wang X, Zhou M, Zhang D, Zhang H, Kong Q, Liu C, Li X, Yu Y, Liu S, Shu L, Ma D, Wei J, Zhang D (2003) Association study between interleukin-1beta gene (IL-1beta) and schizophrenia. Life Sci 72:3017–3021PubMedCrossRefGoogle Scholar
  269. Yee N, Schwarting RK, Fuchs E, Wohr M (2012) Increased affective ultrasonic communication during fear learning in adult male rats exposed to maternal immune activation. J Psychiatr Res 46:1199–1205PubMedCrossRefGoogle Scholar
  270. Yirmiya R (1996) Endotoxin produces a depressive-like episode in rats. Brain Res 711:163–174PubMedCrossRefGoogle Scholar
  271. Zanardini R, Bocchio-Chiavetto L, Scassellati C, Bonvicini C, Tura GB, Rossi G, Perez J, Gennarelli M (2003) Association between IL-1beta -511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia. J Psychiatr Res 37:457–462PubMedCrossRefGoogle Scholar
  272. Zaretsky MV, Alexander JM, Byrd W, Bawdon RE (2004) Transfer of inflammatory cytokines across the placenta. Obstet Gynecol 103:546–550PubMedCrossRefGoogle Scholar
  273. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC (2004) Changes in serum interleukin-2, -6, and −8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 65:940–947PubMedCrossRefGoogle Scholar
  274. Zhang XY, Zhou DF, Qi LY, Chen S, Cao LY, da Chen C, Xiu MH, Wang F, Wu GY, Lu L, Kosten TA, Kosten TR (2009) Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology 204:177–184PubMedCrossRefGoogle Scholar
  275. Ziats MN, Rennert OM (2011) Expression profiling of autism candidate genes during human brain development implicates central immune signaling pathways. PLoS One 6:e24691PubMedCrossRefGoogle Scholar
  276. Zimmerman AW, Jyonouchi H, Comi AM, Connors SL, Milstien S, Varsou A, Heyes MP (2005) Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 33:195–201PubMedCrossRefGoogle Scholar
  277. Zorrilla EP, McKay JR, Luborsky L, Schmidt K (1996) Relation of stressors and depressive symptoms to clinical progression of viral illness. Am J Psychiatry 153:626–635PubMedGoogle Scholar
  278. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R, Seligman DA, Schmidt K (2001) The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 15:199–226PubMedCrossRefGoogle Scholar
  279. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM (2011) Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuro-psychopharmacol Biol Psychiatry 35:722–729CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of ImmunologyRotterdamThe Netherlands
  2. 2.Department of ImmunologyRotterdamThe Netherlands

Personalised recommendations